IL151906A0 - Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 - Google Patents

Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Info

Publication number
IL151906A0
IL151906A0 IL15190601A IL15190601A IL151906A0 IL 151906 A0 IL151906 A0 IL 151906A0 IL 15190601 A IL15190601 A IL 15190601A IL 15190601 A IL15190601 A IL 15190601A IL 151906 A0 IL151906 A0 IL 151906A0
Authority
IL
Israel
Prior art keywords
hodgkin
lymphoma
interleukin
antibody
therapy
Prior art date
Application number
IL15190601A
Other languages
English (en)
Original Assignee
Chiron Corp
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ Rochester filed Critical Chiron Corp
Publication of IL151906A0 publication Critical patent/IL151906A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15190601A 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 IL151906A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19204700P 2000-03-24 2000-03-24
PCT/US2001/009413 WO2001072333A1 (fr) 2000-03-24 2001-03-23 Methodes destinees a traiter un lymphome non hodgkinien au moyen d'une combinaison d'interleukine 2 avec un anticorps anti-cd20

Publications (1)

Publication Number Publication Date
IL151906A0 true IL151906A0 (en) 2003-04-10

Family

ID=22708018

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15190601A IL151906A0 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Country Status (7)

Country Link
US (1) US20020009427A1 (fr)
EP (1) EP1267927A1 (fr)
JP (1) JP2003528155A (fr)
AU (1) AU2001247737A1 (fr)
CA (1) CA2404390A1 (fr)
IL (1) IL151906A0 (fr)
WO (1) WO2001072333A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642596A3 (fr) 1999-05-07 2006-04-12 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
WO2003049694A2 (fr) * 2001-12-07 2003-06-19 Chiron Corporation Methodes therapeutiques de traitement d'un lymphome non hodgkinien
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
AU2015205832A1 (en) * 2002-10-17 2015-08-13 Genmab A/S Human Monoclonal Antibodies Against CD20
BRPI0316779B1 (pt) * 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
JP2006522811A (ja) 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
ES2538469T3 (es) 2003-06-05 2015-06-22 Genentech, Inc. Terapia de combinación para trastornos de células B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
EP1773393A2 (fr) * 2004-05-05 2007-04-18 Genentech, Inc. Prevention d'une maladie auto-immune
SV2006002131A (es) * 2004-06-04 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento de lupus
EP3130349A1 (fr) * 2004-06-04 2017-02-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
WO2006012508A2 (fr) * 2004-07-22 2006-02-02 Genentech, Inc. Procede pour traiter le syndrome de sjogren
CN101087807A (zh) * 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
ZA200705459B (en) * 2005-01-13 2008-09-25 Genentech Inc Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
WO2006127517A2 (fr) * 2005-05-20 2006-11-30 Genentech, Inc. Preparation d'echantillon biologique preleve sur un sujet souffrant de maladie auto-immune
US20080213273A1 (en) 2005-07-25 2008-09-04 Trubion Pharmaceuticals Inc. Single dose use of CD20-specific binding molecules
EP1912675B1 (fr) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) * 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
DE17196350T1 (de) 2007-07-09 2018-12-27 Genentech, Inc. Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
EP2200631A1 (fr) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
WO2010011697A1 (fr) * 2008-07-21 2010-01-28 Immunomedics Inc. Variants structuraux d'anticorps pour obtenir de meilleures caractéristiques thérapeutiques
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
KR20180114966A (ko) 2009-08-11 2018-10-19 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
CN102050879B (zh) * 2009-10-30 2014-02-19 上海抗体药物国家工程研究中心有限公司 抗人cd20人源化抗体、其制备方法及用途
WO2011072333A1 (fr) * 2009-12-15 2011-06-23 Guvera Ip Pty Ltd Système et procédé permettant de produire et d'afficher un contenu représentant une personnalité de marque
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
EP3660035A1 (fr) 2015-05-30 2020-06-03 Molecular Templates, Inc. Supports de sous-unité a de toxine de shiga, déimmunisés, et molécules de ciblage de cellule les comprenant
CA2985718A1 (fr) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anticorps anti-recepteur de la transferrine avec une affinite adaptee
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
CN1320044A (zh) * 1998-08-11 2001-10-31 Idec药物公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法

Also Published As

Publication number Publication date
JP2003528155A (ja) 2003-09-24
AU2001247737A1 (en) 2001-10-08
EP1267927A1 (fr) 2003-01-02
US20020009427A1 (en) 2002-01-24
WO2001072333A1 (fr) 2001-10-04
CA2404390A1 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
IL151906A0 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
IL152896A0 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
PL320337A1 (en) Portable device for immediately analysing body fluids
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EP0703628A3 (fr) Dispositif MOSFET avec mobilité augmentée et méthode de fabrication
IL143797A0 (en) Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
HUP9902327A3 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
AP2000001983A0 (en) Antibodies to cd23 derivatives thereof and their therapeutic uses
EP1438467A4 (fr) Materiau attenuateur de bruit pour vehicules et procede de fabrication
EP1355563A4 (fr) Procedes de prevention et de traitement du cancer au moyen d'anticorps anti-c3b(i)
EP1011725A4 (fr) Anticorps humanises diriges contre gp39 humain, compositions contenant ces anticorps et utilisation therapeutique de ces derniers
AU2001261144A1 (en) Ultrasonic dosage device and method
AU2002362098A8 (en) Methods of therapy for non-hodgkin's lymphoma
FR2813520B1 (fr) Dispositif de maintien corporel pour fauteuil verticalisateur et fauteuil en faisant application
EP1067199A4 (fr) Procede de comptage de micro-organismes et dispositif permettant d'effectuer ledit comptage
AU2439602A (en) Pliable pad for collecting and absorbing liquids
AU2542295A (en) A disposable liquid-absorbent article, method and apparatus for its manufacture
LT96140A (en) The use of fibrin-specific antibody as an antithrombic agent
EP0700832A3 (fr) Appareil pour grouper des sachets
AU5688596A (en) Anti-cd14 antibodies for use in the induction of il-10 secre tion
GB9618945D0 (en) Device for depletion of leukocytes
GB0023654D0 (en) Device for administering doses of particulate material
HU0103040D0 (en) High - level source and it's application
AU2567599A (en) Anti-ccr1 antibodies and methods of use therefor